EUVIMEDEUVIMED entdecken
Crossref

Chitosan-based nanoformulation of lupeol induces autophagy–apoptosis interplay through AMPK/mTOR activation and NF-κB inhibition in colorectal carcinoma

Cletus Anes Ukwubile, Troy Salvia Malgwi, Babagana Modu, Chidi Kaosi Clement

Cancer Advances · 2026 · 9 · e26020

DOI: 10.53388/2026926020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Advances, 2026. Verfasst von Cletus Anes Ukwubile und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal carcinoma (CRC) remains a major cause of cancer-related mortality worldwide, highlighting the need for safer and more effective therapeutic strategies. Lupeol, a naturally occurring pentacyclic triterpenoid found in several medicinal plants, exhibits notable anticancer properties. However, its poor aqueous solubility and low bioavailability limit its clinical application. This study aimed to enhance the therapeutic efficacy of lupeol by developing a chitosan-based nanoformulation for improved delivery against CRC.

Methods

Lupeol-loaded chitosan nanoparticles (Lu-CS NPs) were synthesized and characterized for particle size, surface charge, encapsulation efficiency, and drug release behavior. The anticancer activity of the nanoformulation was evaluated using human CRC cell lines and an HCT116 human colorectal cancer xenograft mouse model ( in vivo ). Cellular responses, including cell viability, reactive oxygen species (ROS) generation, mitochondrial membrane potential, apoptosis, and autophagy, were assessed. Molecular analyses were performed to investigate the involvement of mammalian target of rapamycin (mTOR), nuclear factor kappa B (NF-κ B), and adenosine monophosphate-activated protein kinase (AMPK) signaling pathways, which are known regulators of cancer cell proliferation, inflammation, and metabolic stress responses.

Results

Lu-CS NPs showed a nanoscale size (~180 ± 15 nm), positive surface charge (+32 ± 4 mV), and high encapsulation efficiency (~85%) with sustained lupeol release. Compared with free lupeol, the nanoformulation significantly reduced CRC cell viability, increased ROS production, induced mitochondrial membrane depolarization, and triggered caspase-dependent apoptosis. Enhanced autophagic flux was observed through LC3-II accumulation and p65 degradation. Mechanistically, Lu-CS NPs activated AMPK, inhibited mTOR phosphorylation, and suppressed NF-κ B nuclear translocation. In vivo , the nanoformulation significantly suppressed HCT116 xenograft tumor growth by approximately 62% without observable toxicity.

Conclusion

Chitosan-based nanoencapsulation enhances the anticancer efficacy of lupeol against CRC by promoting autophagy–apoptosis interplay through AMPK/mTOR activation and NF-κ B inhibition, suggesting its potential as a promising nanotherapeutic strategy for colorectal cancer treatment.

Zitieren

APA

Ukwubile, C. A., Malgwi, T. S., Modu, B., & Clement, C. K. (2026). Chitosan-based nanoformulation of lupeol induces autophagy–apoptosis interplay through AMPK/mTOR activation and NF-κB inhibition in colorectal carcinoma. Cancer Advances, 9(0), e26020. https://doi.org/10.53388/2026926020

Vancouver

Ukwubile CA, Malgwi TS, Modu B, Clement CK. Chitosan-based nanoformulation of lupeol induces autophagy–apoptosis interplay through AMPK/mTOR activation and NF-κB inhibition in colorectal carcinoma. Cancer Advances. 2026;9(0):e26020. doi:10.53388/2026926020

BibTeX
@article{Ukwubile2026,
  author = {Ukwubile, Cletus Anes and Malgwi, Troy Salvia and Modu, Babagana and Clement, Chidi Kaosi},
  title = {Chitosan-based nanoformulation of lupeol induces autophagy–apoptosis interplay through AMPK/mTOR activation and NF-κB inhibition in colorectal carcinoma},
  journal = {Cancer Advances},
  year = {2026},
  volume = {9},
  number = {0},
  pages = {e26020},
  doi = {10.53388/2026926020}
}
Kostenlos starten →